Management of Coronary Artery Diseases in Systemic Vasculitides: Complications and Strategies

• Published in: Medicina (Kaunas, Lithuania) Vol. 60; no. 10; p. 1574
• Main Authors: Shumnalieva, Russka, Mileva, Niya, Padjen, Ivan, Siliogkas, Periklis, Chervenkov, Lyubomir, Bakopoulou, Konstantina, Kaouri, Issa El, Vasilska, Anna, Miteva, Dimitrina, Vassilev, Dobrin, Velikova, Tsvetelina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.10.2024; MDPI
• Subjects: Atherosclerosis; Blood vessels; cardiovascular complications; Cardiovascular disease; Care and treatment; Clinical outcomes; Complications and side effects; coronary artery bypass grafting; coronary artery disease; Coronary Artery Disease - complications; Coronary Artery Disease - physiopathology; Coronary heart disease; Coronary vessels; Cytokines; Drug therapy; Heart; Heat shock proteins; Humans; immunosuppressive therapy; Inflammation; Ischemia; Kawasaki disease; Leukocytes; Lymphocytes; Medical Subject Headings-MeSH; Mortality; Myocarditis; Neutrophils; Pathogenesis; Patients; percutaneous coronary intervention; Review; Risk factors; Smooth muscle; systemic vasculitides; Systemic Vasculitis - complications; Systemic Vasculitis - physiopathology; Thromboembolism; Vasculitis; Vein & artery diseases; Bulgaria; coronary artery disease; immunosuppressive therapy; percutaneous coronary intervention; systemic vasculitides; cardiovascular complications; coronary artery bypass grafting; personalized medicine
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina60101574

Coronary artery disease (CAD) presents a significant risk for patients with systemic vasculitides, a group of disorders characterized by the inflammation of blood vessels. In this review, we focus on the pathophysiological mechanisms, complications, and management strategies for CAD in systemic vasculitides. We highlight how the inflammatory processes inherent in vasculitis contribute to accelerated atherosclerosis and myocardial ischemia. Key strategies in managing CAD in this patient population include using medicine treatments to mitigate vascular inflammation while balancing the risk of promoting cardiovascular events and lifestyle modifications. Understanding the nuanced relationship between systemic vasculitides and CAD is crucial for improving patient outcomes and guiding therapeutic approaches.